Table 3.
HPV antibody In HIV-infected and uninfected children at 4–5 years after administration of three doses of quadrivalent HPV vaccine.
| HPV Type | HIV-Infected
|
HIV-Uninfecteda
|
P-value (Infected VS Uninfected)
|
||||
|---|---|---|---|---|---|---|---|
| cLIA (n = 14) | LIA (n = 14) | cLIA (n = 239–241) | LIA (n = 252–254) | cLIA | LIA | ||
| 6 | GM (CI) | 104 (52,206) | 62 (28,103) | 126 110,144) | 127 (111,145) | 0.5652 | 0.0765 |
| Positive | 93% | 86% | 94% | 96% | 0.5834 | 0.1247 | |
| 11 | GM (CI) | 82 (42,158) | 48 (22,104) | 141 (122,163) | 144 (125,167)b | 0.1043 | 0.0095 |
| Positive | 86% | 71% | 97% | 98%c | 0.0814 | 0.0005 | |
| 16 | GM (CI) | 310 (83,1160) | 321 (99,1038) | 534 (457,6230) | 548 (471,639) | 0.6977 | 0.3470 |
| Positiveb | 86% | 100% | 99%c | 99% | 0.0159 | 1.0000 | |
| 18 | GM (CI) | 42 (15,117) | 49 (19,130) | 80 (66,98) | 83 (69,101) | 0.2038 | 0.2747 |
| Positive | 64% | 71% | 77% | 87% | 0.3295 | 0.1120 | |
a
Uninfected comparator group extracted from reference #32. Ferris D, Samakoses R, Block SL; Pediatrics 2014; 134: e657-65.
b
HPV 16 cLIA seropositive % greater for HIV-uninfected (p = 0.016, Fisher’s exact test).